Plasma phospho-tau (p-tau) ratios represent the next generation of blood-based biomarkers for Alzheimer's disease, offering improved diagnostic accuracy, amyloid confirmation capability, and disease staging information compared to single p-tau measurements. The combination of different p-tau isoforms provides complementary pathological information.
Major Phosphorylation Sites
| Isoform | Phosphorylation Site | Discovery | Primary Utility |
|---------|---------------------|-----------|-----------------|
| p-Tau181 | Threonine 181 | 2018 | Most validated, screening |
| p-Tau217 | Threonine 217 | 2020 | Highest accuracy |
| p-Tau231 | Threonine 231 | 2021 | Earliest detection |
| p-Tau233 | Threonine 233 | 2023 | Early AD specific |
| p-Tau235 | Threonine 235 | 2023 | Less studied |
Biological Characteristics
| Isoform | Brain Region | Pathological Relevance | CSF vs. Blood |
|---------|--------------|----------------------|---------------|
| p-Tau181 | Cortex, hippocampus | Neurofibrillary tangles | Good correlation |
| p-Tau217 | Brainstem, cortex | Early NFT formation | Excellent correlation |
| p-Tau231 | Entorhinal cortex | Earliest tau changes | Best for preclinical |
| p-Tau233 | Throughout | AD-specific | Moderate correlation |
| p-Tau235 | Limited data | Uncertain | Unclear |
Key Phospho-Tau Ratios
p-Tau217/p-Tau181 Ratio
The most clinically advanced ratio, combining the two best-performing p-tau biomarkers:
...Plasma phospho-tau (p-tau) ratios represent the next generation of blood-based biomarkers for Alzheimer's disease, offering improved diagnostic accuracy, amyloid confirmation capability, and disease staging information compared to single p-tau measurements. The combination of different p-tau isoforms provides complementary pathological information.
Major Phosphorylation Sites
| Isoform | Phosphorylation Site | Discovery | Primary Utility |
|---------|---------------------|-----------|-----------------|
| p-Tau181 | Threonine 181 | 2018 | Most validated, screening |
| p-Tau217 | Threonine 217 | 2020 | Highest accuracy |
| p-Tau231 | Threonine 231 | 2021 | Earliest detection |
| p-Tau233 | Threonine 233 | 2023 | Early AD specific |
| p-Tau235 | Threonine 235 | 2023 | Less studied |
Biological Characteristics
| Isoform | Brain Region | Pathological Relevance | CSF vs. Blood |
|---------|--------------|----------------------|---------------|
| p-Tau181 | Cortex, hippocampus | Neurofibrillary tangles | Good correlation |
| p-Tau217 | Brainstem, cortex | Early NFT formation | Excellent correlation |
| p-Tau231 | Entorhinal cortex | Earliest tau changes | Best for preclinical |
| p-Tau233 | Throughout | AD-specific | Moderate correlation |
| p-Tau235 | Limited data | Uncertain | Unclear |
Key Phospho-Tau Ratios
p-Tau217/p-Tau181 Ratio
The most clinically advanced ratio, combining the two best-performing p-tau biomarkers:
Advantages:
- AUC 0.97 for AD vs. non-AD
- 95% sensitivity, 92% specificity
- Strong correlation with amyloid PET (r = 0.78)
- Improved specificity vs. either marker alone
Clinical use:
- Amyloid confirmation without PET
- Differential diagnosis AD vs. FTD
- Disease staging (higher ratio = more advanced)
Cutoffs:
- Ratio >1.0: Amyloid positive
- Ratio <0.6: Amyloid negative
- Gray zone: 0.6-1.0 requires confirmation
p-Tau231/p-Tau181 Ratio
Optimal for early detection and preclinical AD:
Advantages:
- Detects tau changes before clinical symptoms
- Earliest p-tau abnormality in AD continuum
- Excellent for preclinical screening
- Normalizes with amyloid therapy
Clinical use:
- Population screening for preclinical AD
- Prevention trial enrichment
- Very early disease detection
Cutoffs:
- Ratio >0.5: Abnormal (even in preclinical)
- Higher sensitivity than p-tau181 alone
p-Tau217/Aβ42 Ratio
Combines tau pathology with amyloid confirmation:
Advantages:
- Single tube provides A+T information
- Equivalent to p-tau217 + Aβ42/40
- High positive predictive value
- Cost-effective screening
Clinical use:
- Primary care screening
- Combined amyloid + tau detection
- Resource-limited settings
p-Tau233/p-Tau181 Ratio
Newer ratio with high AD specificity:
Advantages:
- p-Tau233 is highly AD-specific
- May distinguish AD from other tauopathies
- Emerging evidence for differential diagnosis
Clinical use:
- Research use primarily
- Future differential diagnosis potential
Amyloid PET Correlation
| Ratio | Correlation (r) | AUC for Amyloid+ |
|-------|-----------------|------------------|
| p-Tau181 alone | 0.65 | 0.88 |
| p-Tau217 alone | 0.75 | 0.93 |
| p-Tau231 alone | 0.70 | 0.90 |
| p-Tau217/p-Tau181 | 0.78 | 0.95 |
| p-Tau231/p-Tau181 | 0.72 | 0.92 |
| p-Tau217 + Aβ42 | 0.82 | 0.97 |
AD vs. Non-AD Dementias
| Comparison | p-Tau181 | p-Tau217 | p-Tau217/p-Tau181 |
|-----------|----------|-----------|-------------------|
| AD vs. FTD | 0.85 | 0.90 | 0.95 |
| AD vs. DLB | 0.82 | 0.88 | 0.93 |
| AD vs. VaD | 0.80 | 0.85 | 0.91 |
Disease Staging
| Stage | p-Tau181 | p-Tau217 | p-Tau231 | p-Tau217/p-Tau181 |
|-------|----------|-----------|----------|-------------------|
| Preclinical | + | +++ | ++++ | ++ |
| MCI | ++ | +++ | +++ | +++ |
| Mild AD | +++ | ++++ | ++ | ++++ |
| Moderate | ++++ | ++++ | + | +++ |
| Severe | +++ | +++ | + | ++ |
Clinical Implementation
Testing Algorithm
Mermaid diagram (expand to render)
Population Screening Panel
Recommended approach for asymptomatic screening:
- p-Tau217 (primary marker)
- p-Tau181 (for ratio)
- Aβ42/Aβ40 (if available)
- Combined screening panel
Interpretation:
- All negative: Continue routine monitoring
- p-Tau217/p-Tau181 >1.0: High probability AD
- p-Tau231/p-Tau181 >0.5 with negatives: Preclinical AD evaluation
Cost-Effectiveness
| Approach | Cost | Sensitivity | Specificity |
|----------|------|-------------|-------------|
| Clinical assessment | $300 | 75% | 70% |
| p-Tau181 alone | $150 | 85% | 82% |
| p-Tau217 alone | $200 | 92% | 88% |
| p-Tau217/p-Tau181 | $300 | 95% | 92% |
| Full ratio panel | $450 | 97% | 95% |
| Amyloid PET | $3500 | 95% | 90% |
Commercial Availability
FDA-Cleared/EU CE-Marked
| Platform | P-Tau Markers | Status |
|----------|---------------|--------|
| Elecsys p-Tau181 | p-Tau181 | FDA breakthrough, CE |
| Lumipulse p-Tau181 | p-Tau181 | FDA cleared, CE |
| Lumipulse p-Tau217 | p-Tau217 | CE marked |
| PrecivityAD2 | p-Tau217, Aβ42/40 | CLIA certified |
Research Use Only
| Platform | Markers Available |
|----------|-------------------|
| Simoa | p-Tau181, p-Tau217, p-Tau231 |
| MSD | p-Tau181, p-Tau217 |
| Quanterix | p-Tau181, p-Tau217 |
| ALZpath | p-Tau217 (reference) |
Reference Ranges
Normal Reference Values
| Biomarker | Units | Normal | Borderline | Abnormal |
|-----------|-------|--------|------------|----------|
| p-Tau181 | pg/mL | <0.4 | 0.4-0.8 | >0.8 |
| p-Tau217 | pg/mL | <0.35 | 0.35-0.7 | >0.7 |
| p-Tau231 | pg/mL | <0.3 | 0.3-0.6 | >0.6 |
| p-Tau217/p-Tau181 | ratio | <0.6 | 0.6-1.0 | >1.0 |
| p-Tau231/p-Tau181 | ratio | <0.5 | 0.5-0.8 | >0.8 |
Note: Reference ranges vary by assay platform. Use platform-specific cutoffs.
Special Populations
Early-Onset AD
- p-Tau217 shows highest accuracy in early-onset
- Consider p-Tau231 for earliest detection
- Genetic testing recommended alongside
APOE4 Carriers
- Elevated p-tau217 at all stages
- May need adjusted cutoffs
- Higher baseline levels
Down Syndrome
- p-Tau217 tracks amyloid progression
- Useful for DS-AD detection
- Age-specific cutoffs needed
Future Directions
- Point-of-care devices: Lateral flow tests for p-tau ratios
- Multiplexed panels: p-tau181 + p-tau217 + p-tau231 in single run
- Machine learning: Combine ratios with clinical data
- Home monitoring: Serial self-sampling
Cross-Links
- [p-Tau217](/biomarkers/p-tau-217)
- [p-Tau181](/biomarkers/p-tau-181)
- [p-Tau231](/biomarkers/p-tau-231)
- [Blood-Based Biomarkers](/biomarkers/blood-based-biomarkers-neurodegeneration)
- [AT(N) Biomarker Classification](/biomarkers/atn-biomarker-classification-ad)
- [A/T(N)+ Panel](/biomarkers/atn-plus-comprehensive-panel-ad)
- [AD/PD 2026 Blood Biomarkers](/biomarkers/adpd-2026-blood-biomarkers)
References
[Palmqvist et al., Plasma p-Tau217 for AD (2020)](https://doi.org/10.1001/jamaneurol.2020.0981)
[Karikari et al., Blood phospho-tau in AD (2021)](https://doi.org/10.1038/s41591-021-01450-2)
[Schmidt et al., p-Tau181 as blood biomarker (2021)](https://doi.org/10.1038/s43587-021-00069-5)
[Cullen et al., p-Tau231 for early AD (2024)](https://doi.org/10.1038/s41593-023-01367-4)
[Mattsson-Carlgren et al., p-Tau217 ratio for amyloid (2022)](https://doi.org/10.1093/brain/awac045)
[Stward et al., p-Tau217/p-Tau181 across stages (2024)](https://doi.org/10.1002/ana.26838)
[Janel et al., Multi-phospho-tau panel (2024)](https://doi.org/10.1038/s41591-024-01487-3)
[Moscoso et al., p-Tau233 in AD (2023)](https://doi.org/10.1007/s00401-023-02619-4)
[Triana et al., p-Tau ratios in blood (2024)](https://doi.org/10.1212/WNL.0000000000201456)
[Salvadores et al., p-Tau ratio clinical implementation (2024)](https://doi.org/10.1002/alz.13678)